Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-12-12-Speech-3-198"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20011212.6.3-198"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Question No 5 by Alexandros Alavanos ():
The anthrax crisis in the USA has produced a rise in demand for Cipro, a patented drug manufactured by Bayer. The Canadian Government's response was simply to ask the country's industry to produce 'copies' of the drug. The US Administration appears to be pondering the same course of action as US legislation apparently allows the Administration, when there is a need for a patented drug, to ignore the restrictions imposed by the patent and authorise its manufacture. Evidently double standards are operating in regard to the developing countries' request for a reduction in the price of patented drugs and a relaxation of the legislation protecting patents in order to treat AIDS and other diseases.
Has the Council considered what action it would take in the event of a rise in demand for a particular drug, as has occurred in the USA? Is it consistent with Community law for a Member State to have US-type legislation which allows it to ignore the restrictions imposed by patents? Will it respond positively to the developing countries' request for a price reduction and a relaxation of patent rights, which would clearly be beneficial not only for the developing countries but also for European and American consumers?"@en1
|
lpv:unclassifiedMetadata |
"Subject: Demand for drugs to fight anthrax"1
|
Named graphs describing this resource:
The resource appears as object in 2 triples